Evidence map›Paper›PMID 31687555›Full record

ArticleHeliyon2019

DFT-based reactivity and combined QSAR, molecular docking of 1,2,4,5-Tetrazine derivatives as inhibitors of Pim-1 kinase.

Halima Hazhazi, Nadjib Melkemi, Toufik Salah, Mohammed Bouachrine

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Frontiers in chemistry · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Halima HazhaziGroup of Computational and Pharmaceutical Chemistry, Laboratory of Molecular Chemistry and Environment (LMCE), Department of Chemistry of Sciences, University of Biskra, 07000, Biskra, Algeria.
Nadjib MelkemiGroup of Computational and Pharmaceutical Chemistry, Laboratory of Molecular Chemistry and Environment (LMCE), Department of Chemistry of Sciences, University of Biskra, 07000, Biskra, Algeria.
Toufik SalahGroup of Computational and Pharmaceutical Chemistry, Laboratory of Molecular Chemistry and Environment (LMCE), Department of Chemistry of Sciences, University of Biskra, 07000, Biskra, Algeria.
Mohammed BouachrineMCNS Laboratory, Faculty of Science, Moulay Ismail University of Meknes, Morocco.
University of Biskra · DZUniversité Moulay Ismail de Meknes · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present work we have calculated several DFT reactivity descriptors for 1,2,4,5-Tetrazine at the B3LYP/6-311++G(d,p) level of theory in order to analyze its reactivity in vacuum and solvent phases. Whereas, the influence of the solvent was taken into account employing the PCM model. DFT-based descriptors such as (electronic chemical potential, electrophilicity, condensed Fukui function….) have been determined to predict the reactivity of 1,2,4,5-Tetrazine. A series of eighteen 1,2,4,5-Tetrazine derivatives was studied by using two computational techniques, namely, quantitative structure activity relationship (QSAR) and molecular docking. QSAR models of the antitumor activity of some 1,2,4,5-Tetrazine derivatives were established in gas and solvent phases which exhibited good statistical values for both cases. Whereas, multiple linear regression (MLR) procedure was used to obtain the best QSAR models and the leave-one-out (LOO) method to estimate the predictivity of our models. The most and the least active compounds were docked with the protein (3C4E) to confirm those obtained results from QSAR models and elucidate the binding mode between this type of compounds and corresponding protein.

Indexed as

1,2,4,5-TetrazinesAntitumor activityBioinformaticsDFTMolecular modelingPharmaceutical chemistryQSARSolvent effectTheoretical chemistry

Identifiers

PMID31687555
PMCPMC6819827
OpenAlexW2975999596

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.